CRL250117P220000
- 33.37
- 0.000.00%
Charles River Newsroom
Goldman Sachs Maintains Charles River(CRL.US) With Buy Rating, Cuts Target Price to $190
Goldman Sachs Adjusts Charles River Laboratories International Price Target to $190 From $220, Maintains Buy Rating
Charles River Downgraded to Market Perform From Outperform at William Blair
William Blair Initiates Charles River(CRL.US) With Hold Rating
Charles River Analyst Ratings
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $182
TD Cowen Adjusts Charles River Laboratories International Price Target to $182 From $227
Charles River Labs Cut to Neutral From Buy by UBS
Charles River Analyst Ratings
UBS Downgrades Charles River to Neutral, Lowers Price Target to $185
UBS Downgrades Charles River(CRL.US) to Hold Rating, Cuts Target Price to $185
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating
Evercore Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $195
Evercore ISI Sticks to Their Hold Rating for Charles River Labs (CRL)
Jefferies Adjusts Price Target on Charles River Laboratories International to $169 From $196, Keeps Hold Rating
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Maintains Target Price $227
BofA Securities Downgrades Charles River(CRL.US) to Hold Rating, Cuts Target Price to $210
Citi Maintains Charles River(CRL.US) With Sell Rating, Announces Target Price $175
Charles River Analyst Ratings
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $245 From $250